DUBLIN – Genmab A/S's Duobody bispecific antibody technology received a stamp of approval from the big Kahuna of Danish biopharmas, Novo Nordisk A/S, which is in-licensing two programs that address two different target combinations, in a deal potentially worth up to $500 million in development, regulatory and sales milestones, as well as $2 million up front. Read More
New data revealing the potential for Kempharm Inc.'s hydrocodone prodrug, KP-201 (benzhydrocodone), to deter abuse by yielding lower hydrocodone exposure when snorted vs. generic hydrocodone bitartrate moved the company closer to what it expects will be a fourth quarter FDA NDA filing. Read More
LONDON – The UK's National Institute for Health and Care Excellence (NICE) has issued guidelines to support the systematic introduction of biosimilar infliximab to replace the innovator product, Remicade. Read More
In recent years, technological advances in both biomedical and computer science have contributed to a massive increase in the amount of data available to researchers. What has not quite caught up yet, though, are the statistical methods to analyze such so-called big data. Read More
Onconova Therapeutics Inc. cheered investors by disclosing the submission of an investigational new drug (IND) application to the FDA to test the intravenous (I.V.) formulation of rigosertib in a pivotal phase III study in higher-risk myelodysplastic syndromes (HR-MDS) after the failure of a hypomethylating agent (HMA). Read More
SHANGHAI – Ascentage Pharma Group and its pipeline of small-molecule, apoptosis-targeted cancer agents has bagged $15.5 million in a series A round from a group of Chinese venture investors. Read More
HONG KONG – Disaster preparedness isn't a topic that shows up in frequent biopharma discussions or on conference agendas, but the powerful typhoon that hit Taiwan and Mainland China earlier this month – killing at least 34 people, damaging 65,000 homes and leaving more than 4 million homes without power – highlighted the importance of emergency preparedness for companies in the biopharma space, particularly when setting up shop in a country that is regularly assailed by huge storms and occasional earthquakes. Read More
Emerge Resources Corp., of Vancouver, British Columbia, and Vaxil Biotherapeutics Ltd., of Nes-Ziona, Israel, completed a private placement of approximately $2.7 million by way of subscription receipt. Read More
Prima Biomed Ltd., of Sydney, said it will receive an undisclosed clinical milestone payment from partner Novartis AG, of Basel, Switzerland, related to its phase I IMP701 LAG-3 antibody, in testing against cancer. Read More
Proteon Therapeutics Inc., of Waltham, Mass., reported top-line results from its phase I study of vonapanitase in patients with symptomatic peripheral artery disease, or PAD. Read More
Scientists from the Israeli Tel Aviv University have reported that metabolites can form amyloid fibrils. Though the beta-amyloids of Alzheimer's disease are the most famous amyloid fibrils, technically speaking, any normally soluble proteins that aggregate into insoluble clumps are amyloids. Read More
